paroxetine has been researched along with afimoxifene in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Goetz, MP; Loprinzi, CL | 1 |
| Bhargava, P; Desta, Z; Flockhart, DA; Hayes, DF; Johnson, MD; Morocho, A; Novielli, A; Rae, JM; Stearns, V | 1 |
| Bean, GR; Dietze, EC; Moore, C; Ratliff, B; Seewaldt, VL; Wanko, S | 1 |
| Garber, K | 1 |
1 review(s) available for paroxetine and afimoxifene
| Article | Year |
|---|---|
A hot flash on tamoxifen metabolism.
Topics: Antidepressive Agents, Second-Generation; Antineoplastic Agents, Hormonal; Breast Neoplasms; Cyclohexanols; Cytochrome P-450 CYP2D6; Estrogen Receptor Modulators; Estrogen Replacement Therapy; Female; Fluoxetine; Hot Flashes; Humans; Hydroxylation; Paroxetine; Randomized Controlled Trials as Topic; Selective Estrogen Receptor Modulators; Tamoxifen; Venlafaxine Hydrochloride | 2003 |
1 trial(s) available for paroxetine and afimoxifene
| Article | Year |
|---|---|
Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine.
Topics: Adult; Aged; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cytochrome P-450 CYP2D6 Inhibitors; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Enzyme Inhibitors; Female; Humans; Microsomes, Liver; Middle Aged; Paroxetine; Prospective Studies; Selective Estrogen Receptor Modulators; Selective Serotonin Reuptake Inhibitors; Tamoxifen; Treatment Outcome | 2003 |
2 other study(ies) available for paroxetine and afimoxifene
| Article | Year |
|---|---|
Re: Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine.
Topics: Antidepressive Agents, Second-Generation; Antineoplastic Agents, Hormonal; Estrogen Receptor Modulators; Female; Humans; Paroxetine; Selective Serotonin Reuptake Inhibitors; Tamoxifen | 2004 |
Tamoxifen pharmacogenetics moves closer to reality.
Topics: Antidepressive Agents, Second-Generation; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP2D6 Inhibitors; Enzyme Inhibitors; Estrogen Receptor Modulators; Genotype; Hot Flashes; Humans; Paroxetine; Pharmacogenetics; Polymorphism, Genetic; Predictive Value of Tests; Tamoxifen | 2005 |